Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;50(1):121-7.
doi: 10.1016/j.ejca.2013.09.007. Epub 2013 Oct 4.

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

Michele Del Vecchio  1 , Lorenza Di Guardo  2 , Paolo A Ascierto  3 , Antonio M Grimaldi  3 , Vanna Chiarion Sileni  4 , Jacopo Pigozzo  4 , Virginia Ferraresi  5 , Carmen Nuzzo  5 , Gaetana Rinaldi  6 , Alessandro Testori  7 , Pier F Ferrucci  8 , Paolo Marchetti  9 , Federica De Galitiis  10 , Paola Queirolo  11 , Elena Tornari  11 , Riccardo Marconcini  12 , Luana Calabrò  13 , Michele Maio  13
Affiliations

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

Michele Del Vecchio et al. Eur J Cancer. 2014 Jan.

Abstract

Background: Mucosal melanoma is an extremely rare and aggressive malignancy that often remains undetected until it reaches an advanced stage, when effective treatment options are limited. The activity and safety of ipilimumab were assessed in an Expanded Access Programme (EAP) that included patients with metastatic, mucosal melanoma.

Methods: Ipilimumab was available upon physician request for patients aged ⩾16years with stage III (unresectable) or IV skin, ocular or mucosal melanoma, who had failed or did not tolerate previous treatments and had no other therapeutic option available. Patients received ipilimumab 3mg/kg every 3weeks for four doses. Patients with stable disease or an objective response to ipilimumab were eligible for retreatment upon disease progression. Tumour assessments were conducted at baseline and week 12 using immune-related response criteria. Patients were monitored for adverse events (AEs), including immune-related AEs, within 3 to 4days of each scheduled visit.

Results: Of 855 patients participating in the EAP in Italy, 71 (8%) had metastatic, mucosal melanoma. With a median follow-up of 21.8months, the response rate was 12% and the immune-related disease control rate was 36%. Median progression-free survival and overall survival were 4.3 and 6.4months, respectively. In total, 34% of patients reported treatment-related AEs of any grade, which were grade 3 or 4 in 9% of patients. AEs were generally manageable as per protocol-specific guidelines.

Conclusion/interpretation: Ipilimumab may be a feasible treatment option in pretreated patients with metastatic mucosal melanoma, and warrants further investigation in prospective clinical trials.

Keywords: Efficacy; Expanded access programme; Ipilimumab; Metastatic melanoma; Mucosal; Safety.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources